Rigel Pharmaceuticals (RIGL) Change in Accured Expenses (2010 - 2026)

Rigel Pharmaceuticals' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$5.9 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 43.5% year-over-year to -$5.9 million; the TTM figure through Mar 2026 stood at -$2.1 million (down 366.71% YoY), while the FY2025 annual figure was -$285000.0, down 119.48% from the prior year.
• Change in Accured Expenses was -$5.9 million for Q1 2026 at Rigel Pharmaceuticals, down from -$211000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.3 million in Q2 2025 to a low of -$5.9 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$556176.5 across 5 years, with a median of $429000.0 in 2023.
• Biggest YoY gain for Change in Accured Expenses was 3627.87% in 2022; the steepest drop was 480.8% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at -$4.7 million in 2022, then surged by 118.23% to $853000.0 in 2023, then surged by 159.67% to $2.2 million in 2024, then tumbled by 109.53% to -$211000.0 in 2025, then sank by 2698.58% to -$5.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.9 million (Q1 2026), -$211000.0 (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.